<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00593593</url>
  </required_header>
  <id_info>
    <org_study_id>104244</org_study_id>
    <secondary_id>Avodart-pv/GR</secondary_id>
    <nct_id>NCT00593593</nct_id>
  </id_info>
  <brief_title>Pharmacovigilance Study To Evaluate Safety Of AVODART In Subjects With Benign Prostate Hyperplasia</brief_title>
  <official_title>A Pharmacovigilance Study to Evaluate Safety of AVODART (Dutasteride) Administration 0,5 mg Once Daily, for 52 Weeks, in Subjects With Benign Prostate Hyperplasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      This study has 4 phases: screening phase (visit 1), treatment phase (visit 2 - 6 mths after
      treatment initiation), and end of treatment phase (visit 3 - end of year 1). Only in the case
      a serious adverse event (SAE) arises, will there be a follow up phase (visit 4).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2004</start_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment>1000</enrollment>
  <condition>Benign Prostatic Hyperplasia</condition>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject should fulfil criteria for the subscription of AVODART as these are mentioned
             in the SPC

          -  Subject should be diagnosed with benign prostate hyperplasia

          -  Subject's prostate volume should be equal or greater than 30 cm3

        Exclusion Criteria:

          -  Known hypersensitivity to any of the AVODART compounds

          -  Suffers from a serious illness which either is not properly controlled or as per
             investigator´s judgment could interfere with the subject´s compliance into the trial

          -  Receives treatment with enzyme inhibitors CYP3A4 and CYP3A5.

          -  History of severe liver failure
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials, MD</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <removed_countries>
    <country>Greece</country>
  </removed_countries>
  <verification_date>October 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 3, 2008</study_first_submitted>
  <study_first_submitted_qc>January 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2008</study_first_posted>
  <last_update_submitted>October 13, 2008</last_update_submitted>
  <last_update_submitted_qc>October 13, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 15, 2008</last_update_posted>
  <responsible_party>
    <name_title>Study Director</name_title>
    <organization>GSK</organization>
  </responsible_party>
  <keyword>benign prostate hyperplasia</keyword>
  <keyword>Dutasteride</keyword>
  <keyword>pharmacovigilance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Prostatic Hyperplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dutasteride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

